Skip to main content
letter
. 2020 Oct 7;37(3):500–502. doi: 10.1007/s12288-020-01362-0

Fig. 1.

Fig. 1

Upper panel shows the demographic and donor details and transplant related details of the 3 patients in a tabular format, middle panel shows the flow cytometric MRD of patient 1 (along with the treatments received) and lower panel shows the serial SUVmax (blue line) and donor chimerism (red line) of patient 2 at various time points. MRD measurable residual disease, Cy Cyclophosphamide, TBI Total Body Irradiation, CsA Cyclosporine, MTX Methotrexate, Len Lenalidomide (color figure online)